Neuroprotective Therapy of Chronic Cerebral Ischemia in Out-Patient Conditions

Objectives. To conduct a differential analysis of the efficacy of combined treatment using drugs with different mechanisms of action (Mexidol, aescusan, Halidor) in patients with chronic cerebral ischemia (CCI) stages I, II, and III in out-patient conditions. Materials and methods. The study included 50 patients with diagnoses of chronic cerebral ischemia stages I–III of atherosclerotic, hypertensive, and mixed origin (20 patients with stage I, 20 with stage II, and 10 with stage III). On the background of basal treatment, patients received three courses of combined therapy with Mexidol, Halidor, and aescusan for six weeks with three-month intervals between courses. Changes in patients' subjective complaints and objective clinical signs were evaluated after each course. Results and conclusions. Clinical neurological investigations demonstrated the therapeutic efficacy of prolonged complex treatment with different courses of antioxidants. Use of the combination of Mexidol, aescusan, and Halidor promoted improvements in cognitive, adaptive, and motor functions in patients with CCI stages I and II. Increases in treatment efficacy were obtained in patients with CCI stage III by supplementing the neuroprotective actions of the drugs used with agents improving cognitive functions.

http://ift.tt/2gLAOJW